The estimated Net Worth of Neil Kumar is at least $200 Million dollars as of 16 August 2024. Neil Kumar owns over 55,537 units of BridgeBio Pharma Inc stock worth over $138,633,910 and over the last 6 years he sold BBIO stock worth over $35,393,755. In addition, he makes $26,334,100 as Chief Executive Officer and Director at BridgeBio Pharma Inc.
Sign up
Neil Kumar BBIO stock SEC Form 4 insiders trading
Neil has made over 40 trades of the BridgeBio Pharma Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 55,537 units of BBIO stock worth $1,554,481 on 16 August 2024.
The largest trade he's ever made was buying 1,103,848 units of BridgeBio Pharma Inc stock on 24 May 2019 worth over $28,622,779. On average, Neil trades about 120,689 units every 49 days since 2018. As of 16 August 2024 he still owns at least 4,952,980 units of BridgeBio Pharma Inc stock.
You can see the complete history of Neil Kumar stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Neil Kumar biography
Dr. Neil Kumar Ph.D. serves as Chief Executive Officer, Director of the Company. Dr. Kumar has also served as the Chief Executive Officer of our subsidiary, Eidos Therapeutics (Nasdaq: EIDX), a clinical stage biopharmaceutical company, and a member of Eidos Therapeutics’ board of directors since March 2016. Prior to that, he served as the interim vice president of business development at MyoKardia, Inc. (Nasdaq: MYOK), a clinical stage biopharmaceutical company, from 2012 to 2014. Prior to that, Dr. Kumar served as a principal at Third Rock Ventures, a venture capital firm, from 2011 to 2014. Before joining Third Rock Ventures, he served as an associate principal at McKinsey & Company, a worldwide management consulting firm, from 2007 to 2011. He received his B.S. and M.S. degrees in chemical engineering from Stanford University and received his Ph.D. in chemical engineering from the Massachusetts Institute of Technology. Dr. Kumar’s qualifications to serve on our Board of Directors include his role as our principal executive officer and his extensive experience as an executive officer of biotechnology companies.
What is the salary of Neil Kumar?
As the Chief Executive Officer and Director of BridgeBio Pharma Inc, the total compensation of Neil Kumar at BridgeBio Pharma Inc is $26,334,100. There are no executives at BridgeBio Pharma Inc getting paid more.
How old is Neil Kumar?
Neil Kumar is 41, he's been the Chief Executive Officer and Director of BridgeBio Pharma Inc since 2015. There are 16 older and 6 younger executives at BridgeBio Pharma Inc. The oldest executive at BridgeBio Pharma Inc is Dr. Charles J. Homcy M.D., 73, who is the Chairman of Pharmaceuticals & Lead Director.
What's Neil Kumar's mailing address?
Neil's mailing address filed with the SEC is C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO, CA, 94304.
Insiders trading at BridgeBio Pharma Inc
Over the last 5 years, insiders at BridgeBio Pharma Inc have traded over $409,396,563 worth of BridgeBio Pharma Inc stock and bought 12,280,644 units worth $209,241,115 . The most active insiders traders include Global Investors Lp Viking ..., Andrew Lo, and Genetic Disorder L.P.Kkr Ge.... On average, BridgeBio Pharma Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,173,197. The most recent stock trade was executed by Neil Kumar on 16 August 2024, trading 55,537 units of BBIO stock currently worth $1,554,481.
What does BridgeBio Pharma Inc do?
we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.
What does BridgeBio Pharma Inc's logo look like?
Complete history of Neil Kumar stock trades at Eidos Therapeutics Inc and BridgeBio Pharma Inc
BridgeBio Pharma Inc executives and stock owners
BridgeBio Pharma Inc executives and other stock owners filed with the SEC include:
-
Neil Kumar,
Chief Executive Officer, Director -
Charles Homcy,
Chairman of Pharmaceuticals, Lead Director -
Uma Sinha,
Chief Scientific Officer -
Brian Stephenson,
Chief Financial Officer -
Eric Aguiar,
Independent Director -
Ali Satvat,
Independent Director -
Jennifer Cook,
Independent Director -
Dr. Neil Kumar Ph.D.,
Co-Founder, CEO & Director -
Dr. Brian C. Stephenson C.F.A., Ph.D.,
CFO, Sec. & Principal Accounting Officer -
James Momtazee,
Independent Director -
Richard Scheller,
Chairman of Research and Development, Director -
Dr. Michael Thomas Henderson M.D.,
Chief Bus. Officer -
Dr. Charles J. Homcy M.D.,
Chairman of Pharmaceuticals & Lead Director -
Dr. Richard H. Scheller Ph.D.,
Chairman of R&D and Director -
Dr. Cameron Turtle DPHIL, Ph.D.,
Chief Strategy Officer -
Randal Scott,
Independent Director -
Brenton Saunders,
Independent Director -
Andrew Lo,
Independent Director -
Ronald Daniels,
Independent Director -
Michael Henderson,
Chief Business Officer -
Cameron Turtle,
Senior Vice President - Portfolio Management and Corporate Development -
Frank Mccormick,
Chairman of Oncology -
Dr. Frank McCormick Ph.D.,
Chairman of Oncology -
Grace Rauh,
VP of Communications -
Dr. Uma Sinha Ph.D.,
Chief Scientific Officer -
Yi Ching Yau,
Chief Accounting Officer -
Genetic Disorder L.P.Kkr Ge...,
-
Management Holdings L.P.Kkr...,
-
Douglas A. Dachille,
-
Fred Hassan,
-
Global Performance Llc Viki...,
-
Global Investors Lp Viking ...,
-
Genetic Disorder L.P.Robert...,
-
Yi Ching Yau,
Chief Accounting Officer -
Brian M. Stolz,
Chief Operating Officer -
Hannah Valantine,
-
Brent L Saunders,
Director -
Andrea Ellis,
-
Global Investors Lp Viking ...,
-
Thomas Trimarchi,
President and COO